Emergence of Treatment for multiple sclerosis patients failed in treatment

Multiple sclerosis(MS) patients who failed in treatment have now found an alternative.

The Ministry of Health and Welfare decided to accept the health insurance benefit of Genzyme’s ‘Lemtrada(alemtuzumab)’ on relapsing-remitting multiple sclerosis(RRMS) patients who failed in treating the disease with or are intolerant to the primary treatment(such as interferon).

Currently, there are once-ev...